Source:http://linkedlifedata.com/resource/pubmed/id/18784278
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
24
|
pubmed:dateCreated |
2008-11-27
|
pubmed:abstractText |
Antisense oligonucleotides (AOs) have the potential to induce functional dystrophin protein expression via exon skipping by restoring in-frame transcripts in the majority of patients suffering from Duchenne muscular dystrophy (DMD). AOs of morpholino phosphoroamidate (PMO) and 2'-O-methyl phosphorothioate RNA (2'Ome RNA) chemistry have been shown to restore dystrophin expression in skeletal muscle but not in heart, following high-dose systemic delivery in murine models of muscular dystrophy (mdx). Exploiting the cell transduction properties of two basic arginine-rich cell penetrating peptides, we demonstrate widespread systemic correction of dystrophin expression in body-wide muscles and cardiac tissue in adult dystrophic mdx mice, with a single low-dose injection of peptide-conjugated PMO AO. This approach was sufficient to restore uniform, high-level dystrophin protein expression in peripheral muscle and cardiac tissue, with robust sarcolemmal relocalization of the dystrophin-associated protein complex and functional improvement in muscle. Peptide-conjugated AOs therefore have significant potential for systemic correction of the DMD phenotype.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dystrophin,
http://linkedlifedata.com/resource/pubmed/chemical/Morpholines,
http://linkedlifedata.com/resource/pubmed/chemical/Morpholinos,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotides, Antisense,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1460-2083
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3909-18
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:18784278-Animals,
pubmed-meshheading:18784278-Cell Membrane Permeability,
pubmed-meshheading:18784278-Dose-Response Relationship, Drug,
pubmed-meshheading:18784278-Dystrophin,
pubmed-meshheading:18784278-Gene Expression Regulation,
pubmed-meshheading:18784278-Heart Injuries,
pubmed-meshheading:18784278-Mice,
pubmed-meshheading:18784278-Mice, Inbred C57BL,
pubmed-meshheading:18784278-Mice, Inbred mdx,
pubmed-meshheading:18784278-Morpholines,
pubmed-meshheading:18784278-Morpholinos,
pubmed-meshheading:18784278-Muscle, Skeletal,
pubmed-meshheading:18784278-Muscular Dystrophy, Animal,
pubmed-meshheading:18784278-Oligonucleotides, Antisense,
pubmed-meshheading:18784278-Peptides
|
pubmed:year |
2008
|
pubmed:articleTitle |
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.
|
pubmed:affiliation |
Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|